Our July 2008 supplement on Biologics and Benefit Design, funded by Amgen Inc, (Am J Manag Care. 2008;14[suppl 8]:S241-S268), included an error of omission on the Participant Disclosures page.
The following disclosures for Robert Berglund should have been noted on S244:
Robert Berglund
Honoraria, Amgen Inc
Telephone Follow-Up on Medicare Patient Surveys Remains Critical
January 16th 2025Including a telephone component in Medicare Consumer Assessment of Healthcare Providers and Systems survey administration continues to be valuable because telephone responses comprise a substantial portion of responses for several underserved groups.
Read More
Quantifying the Altruism Value for a Rare Pediatric Disease: Duchenne Muscular Dystrophy
January 14th 2025Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.
Read More